Jhubei, Taiwan

Chia-Chen Lau

This inventor holds 1 USPTO granted patent. Top assignee: Tzu Chi University. Active years: 2019.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chia-Chen Lau: Innovator in Anti-Oral Cancer Drug Development

Introduction

Chia-Chen Lau is a notable inventor based in Jhubei, Taiwan. He has made significant contributions to the field of cancer research, particularly in the development of anti-oral cancer drugs. His innovative work focuses on utilizing unique chemical compounds to combat the proliferation of cancer cells.

Latest Patents

Chia-Chen Lau holds a patent for the "Use of a polyenylpyrrole derivative in preparation of anti-oral cancer drugs." This invention discloses the application of a polyenylpyrrole derivative synthesized from polyvinylpyrrole, auxarconjugatin A, and 12E-isorumbrin. The compound has been shown to inhibit cell proliferation, migration, tumor sphere formation abilities, and xenograft tumorigenicity of oral cancer cells. He has 1 patent to his name.

Career Highlights

Lau is affiliated with Tzu Chi University, where he conducts his research and development work. His academic background and research focus have positioned him as a key player in the fight against oral cancer. His dedication to innovation in this field is evident through his patent and ongoing research efforts.

Collaborations

Chia-Chen Lau collaborates with esteemed colleagues such as Kuo-Feng Hua and Yulin Lam. Their combined expertise enhances the research initiatives at Tzu Chi University, fostering an environment of innovation and discovery.

Conclusion

Chia-Chen Lau's contributions to anti-cancer drug development highlight his commitment to advancing medical science. His innovative approach and successful patent demonstrate the potential for new treatments in the fight against oral cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…